Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Melchior
P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients
Pharmacogenomics and Personalized Medicine
Molecular Medicine
Pharmacology
Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance
EBioMedicine
Biochemistry
Medicine
Genetics
Molecular Biology
P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer
European Journal of Cancer
Cancer Research
Oncology
Brigatinib Bei ALK-positivem NSCLC
Im Focus Onkologie
Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient
Molecular and Clinical Oncology
Cancer Research
Oncology
Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary